Tolerance to peripheral, but not central, effects of ropinirole, a selective dopamine D2-like receptor agonist-Reference-Cited by-同舟云学术

Tolerance to peripheral, but not central, effects of ropinirole, a selective dopamine D2-like receptor agonist

Published:1994-11 Issue:1-2 Volume:265 Page:17-26
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Parker Stephen G.,Raval Pravin,Yeulet Stephanie,Eden Roger J.

Publisher

Elsevier BV

Subject

Pharmacology

Reference29 articles.

1. Pharmacological activity of a novel dopamine D2 agonist (SK&F 101468) in man;Bottomley,1990

2. Pre-junctional regulation of sympathetic neurotransmission in the mouse vas deferens: assessment of agonist and antagonist potencies;Carratu;J. Auton. Nerv. Syst.,1990

3. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve;Chiou;J. Pharmacokinet. Biopharm.,1978

4. Involvement of presynaptic dopamine receptors in the antihypertensive response to 2-NN-dimethylamino-5,6-dihydroxy-1.2.3.4-tetrahydronapthaline (M7);Clapham;J. Pharm. Pharmacol.,1982

5. Tolerance to the cardiovascular effects of SK&F 101468A, a dopamine D2-receptor agonist, in spontaneously hypertensive rats (SHR);Eden;Br. J. Pharmacol.,1988

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety considerations when using non-ergot dopamine agonists to treat Parkinson’s disease;Expert Opinion on Drug Safety;2020-09-01

2. Dual Effects of Hyperprolactinemia on Carrageenan-Induced Inflammatory Paw Edema in Rats;Neuroimmunomodulation;2011

3. Neurogenic orthostatic hypotension of Parkinson's disease: What exploration for what treatment?;Revue Neurologique;2010-10

4. Obesity, dopamine and the metabolic syndrome: potential of dopaminergic agents in the control of metabolism;Current Opinion in Endocrinology & Diabetes;2006-04

5. Prevalence and Costs of Parkinsonian Syndromes Associated with Orthostatic Hypotension;Therapies;2006-03